Incidence and Risk of Influenza in Myasthenic Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03884777 |
Recruitment Status :
Completed
First Posted : March 21, 2019
Last Update Posted : March 21, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Upper respiratory infection , including influenza, may exacerbate the symptoms of myasthenia gravis (MG), which is an autoimmune disease that causes muscle weakness and, in some cases, can precipitate a myasthenic crisis
In the present study, we investigated the incidence and risk factors of influenza infection on in myasthenia gravis patients.
Condition or disease |
---|
Myasthenic Crisis Upper Respiratory Infection |
This is a descriptive study. The data will be analyzed retrospectively . Inclusion of 416 cases of influenza in myasthenic patients treated in the intensive care unit of Garches Hospital between January 1, 2009 and December 31, 2017.
Patients who meet the inclusion and non inclusion criteria and do not object to participate in the study will be collected in a database for analysis.
Study Type : | Observational |
Actual Enrollment : | 400 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Incidence and Risk of Influenza in Myasthenic Patients Hospitalized in Intensive Care |
Actual Study Start Date : | January 1, 2009 |
Actual Primary Completion Date : | December 31, 2017 |
Actual Study Completion Date : | December 31, 2017 |

- Incidence of influenza in myasthenic patient in crisis [ Time Frame: between January 1, 2009 and December 31, 2017. ]Number of influenza cases in myasthenic patients
- Risk factors for poor outcomes [ Time Frame: between January 1, 2009 and December 31, 2017. ]To identify risk factors for severe influenza in myasthenic patients

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Men or women over the age of 18.
- Myasthenic patients hospitalized in intensive care.
- Patients with confirmed influenza infection
Exclusion Criteria:
- Age <18 years,
- Other neuromuscular diseases,
- Patient opposing the use of his data

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03884777
Study Director: | Rania BOUNAB, Dr | Raymond Poincaré Hospital |
Responsible Party: | Centre d'Investigation Clinique et Technologique 805 |
ClinicalTrials.gov Identifier: | NCT03884777 |
Other Study ID Numbers: |
CIC1429 |
First Posted: | March 21, 2019 Key Record Dates |
Last Update Posted: | March 21, 2019 |
Last Verified: | December 2017 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Influenza A virus myasthenia gravis neurocritical care clinical neuromuscular disease |
Respiratory Tract Infections Influenza, Human Orthomyxoviridae Infections RNA Virus Infections |
Virus Diseases Respiratory Tract Diseases Infection |